Novel psilocin prodrugs with altered pharmacological properties as candidate therapies for treatment-resistant anxiety disorders
S. A. Raithatha, J. M. Hagel, K. Matinkhoo, L. Yu, D. Press, S. G. Cook, G. Sharma, D. Dhananjaya, G. Jensen, J. B. Lee, C. Cai, J. Gallant, J. S. Bains, J. E. Tucker, P. J. Facchini
This paper identifies novel psilocin prodrugs with altered pharmacokinetics and reduced psychedelic effects, maintaining therapeutic benefits for anxiety disorders.
bioRxiv · May 16, 2023Pharmacology & Toxicology